secwatch.observer — SEC 8-K summary
======================================

Issuer:     Greenwich LifeSciences, Inc. (GLSI)
CIK:        0001799788
Form:       8-K
Filed at:   2022-07-11T23:59:59+00:00
Accession:  0001493152-22-019022
Event type: regulatory
Sentiment:  negative
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

FDA clinical hold on GLSI-100 Phase III Flamingo-01 remains; manufacturing data submitted, review ongoing
--------------------------------------------------------------------------------

- FDA placed clinical hold on Flamingo-01 trial for GLSI-100 (GP2) in HER2/neu positive patients, citing manufacturing issues.
- Company completed manufacturing of three clinical lots of GP2 that meet release specifications; third lot made on commercial automated filling line.
- FDA is reviewing manufacturing data and sent follow-up questions; company has responded.
- Site initiation visits being scheduled to train clinicians and activate clinical sites.
- No assurance when or if clinical hold will be released; risk factor supplemented.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1799788/000149315222019022/0001493152-22-019022-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1799788/000149315222019022/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-019022

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer